Nuvectis Pharma, Inc. (NVCT) Cash Flow Statement

Nuvectis Pharma, Inc. (NVCT) generated -$19.5M of operating cash flow over the twelve months to 2026-06-30, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NVCTNuvectis Pharma, Inc.Follow NVCT — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 653.3M
P/E TTM: —
Dividend yield: 0.0%
52-week: —
Next earnings: 10 Nov, in 17 days

Line	FY2022 Dec 22	FY2023 Dec 23	FY2024 Dec 24	FY2025 Dec 25	TTM Jun 26	Trend
Operating cash flow	-13.6	-16.0	-12.2	-16.0	-19.5
Stock-based compensation	1.7	4.7	4.9	6.0	—

USD millions · SEC XBRL

Nuvectis Pharma, Inc. — questions

What is Nuvectis Pharma, Inc.'s operating cash flow?: -$19.5M over the twelve months to 2026-06-30.

Every figure on this page comes from Nuvectis Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.